Latest News-HISTOINDEX PTE. LTD Mediaroom_Page

HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023

Data from MAESTRO-NASH study revealed that HistoIndex's technology identified larger percentage of ...

2023-06-21 20:00 2176

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine

SINGAPORE, June 15, 2023 /PRNewswire/ -- HistoIndex has announced that its novel technology combin...

2023-06-15 20:00 1845

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

SINGAPORE, June 15, 2023 /PRNewswire/ -- Recent findings from the TANDEM study (NCT03517540) in 193...

2023-06-15 20:00 1803

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

HistoIndex embarks on partnership with VCU's Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases

Advancing ML/AI-based technology in the study of liver diseases by furthering strategic partnership...

2023-04-10 19:00 2186

Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman

SINGAPORE, Jan. 10, 2023 /PRNewswire/ -- The Board of Directors (the "Board") of HistoIndex (the "C...

2023-01-10 13:01 1637

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial

SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digit...

2022-07-29 19:00 1853

HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors

SINGAPORE, May 18, 2022 /PRNewswire/ -- HistoIndex , a global leading ...

2022-05-18 19:00 1874

HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

* This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine arti...

2022-04-27 17:34 1915

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

Biobot Surgical signs MOU with BEBIG Medical to collaborate on a robotic-guided prostate brachytherapy solution

SINGAPORE, March 11, 2022 /PRNewswire/ -- Biobot Surgical, a robotic-assisted percutaneous surgical...

2022-03-11 13:00 2550

Biobot Surgical signs MOU with BEBIG Medical to collaborate on a robotic-guided prostate brachytherapy solution

SINGAPORE, March 11, 2022 /PRNewswire/ -- Biobot Surgical, a robotic-assisted percutaneous surgical...

2022-03-11 13:00 2207

New Robotic Assisted Transperineal Needle-Guidance System for Prostate Biopsy and Cancer Ablations Received U.S FDA 510(k) Clearance

SINGAPORE, March 5, 2022 /PRNewswire/ -- Biobot Surgical is excited to announce U.S. FDA 510(k) cle...

2022-03-05 20:00 3338

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- HistoIndex , a global leading...

2021-10-20 18:00 1447

HistoIndex's Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet's NASH FASCINATE-2 Phase 2b Clinical Trial

SINGAPORE, Aug. 18, 2021 /PRNewswire/ -- HistoIndex , a global leading...

2021-08-18 18:00 1408

HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo

SINGAPORE, June 25, 2021 /PRNewswire/ -- HistoIndex 's Second Harmonic...

2021-06-25 18:30 1959

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- HistoIndex 's stain-free AI ...

2021-01-25 06:00 1627

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

HistoIndex and Consortium Partners Awarded S$1.2M for the Development of AI-based Diagnostics Tool in the Identification of High-Risk Nonalcoholic Fatty Liver Disease Population

* HistoIndex joins forces with a consortium of partners from NHS Health Boards, UK universities an...

2020-12-15 12:00 703

HistoIndex's AI-Based Platform Demonstrates Zonal Quantification and Histological Characterization of Fibrosis Improvements in Patients With Nonalcoholic Steatohepatitis (NASH)

SINGAPORE, Nov. 18, 2020 /PRNewswire/ -- HistoIndex 's Second Harmoni...

2020-11-18 20:00 1426

Endofotonics Raises S$12 million in Series B Funding for the Commercialization of its AI Powered Medical Device to Support Clinicians in the Real Time Detection of Early Stomach Cancer

SINGAPORE, May 29, 2020 /PRNewswire/ -- Endofotonics announced earli...

2020-05-29 07:00 4480

HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

SINGAPORE, May 25, 2020 /PRNewswire/ -- Singapore medtech company HistoIndex

2020-05-25 06:00 3127

HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features

SINGAPORE, Nov. 11, 2019 /PRNewswire/ -- qFIBS, a novel automated algorithm developed byHistoIndex ...

2019-11-11 13:28 2382